Our bodies have special genes called tumor suppressors that act like a security team for our cells. They make proteins that fix broken DNA, keeping harmful changes from building up.
When these genes stop working or are missing, the risk of cancer goes up. But researchers have now discovered that too much of a DNA‑repair protein can be just as dangerous.
A team at Penn State College of Medicine studied a gene named EXO1. They found that when cells make too much EXO1, it stops fixing DNA and starts chopping it apart, making the genome unstable—a hallmark of cancer.
Data from the Cancer Genome Atlas showed that 20‑30% of breast, ovarian, melanoma, testicular, cervical and liver‑related cancers have high EXO1 levels. The protein behaved like the well‑known BRCA mutations that raise the chance of hereditary breast and ovarian cancers, even though the patients had no BRCA changes.
Why High EXO1 Matters
Normally, EXO1 works like a pair of tiny scissors, trimming and repairing damaged DNA. When the scissors are over‑active, they start cutting parts of DNA that should stay whole.
Lab experiments with human cancer cells showed two ways excess EXO1 harms DNA:
- It creates larger single‑stranded gaps in the DNA.
- It breaks down reversed replication forks, which are important for copying DNA safely.
Both actions lead to loss of genetic material and make the cells more likely to become cancerous.
EXO1 Acts Like a BRCA Loss
BRCA proteins normally protect fragile DNA structures during cell division. When BRCA is mutated, this protection disappears. The study found that too much EXO1 can overwhelm the same protective steps, even when BRCA is perfectly normal.
EXO1 also teams up with another protein called MRE11 to widen DNA gaps and cause dangerous breaks, mimicking the effect of a missing BRCA pathway.
Implications for Treatment
Because tumors with high EXO1 act like BRCA‑mutant cancers, the researchers tested whether they would respond to the same drugs. They used olaparib, a medicine that blocks DNA repair in BRCA‑deficient tumors, and found that EXO1‑rich cancers were very sensitive to it.
The team also saw strong responses to the chemotherapy drug cisplatin. This suggests that patients with EXO1 overexpression might benefit from lower drug doses, reducing side‑effects.
Since EXO1 overproduction appears in many cancer types—more than BRCA mutations alone—it could become a useful marker to guide personalized therapy.
Future Directions
The scientists plan to move forward with clinical trials that target tumors with too much EXO1. If successful, doctors could treat cancers based on their genetic landscape rather than the organ they started in, making treatments more effective.